# Clinical Trial of ARQ 761 in Advanced Solid Tumors

> **NCT01502800** · PHASE1 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 91 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ARQ 761
- **DRUG:** ARQ 761 Weekly Administration
- **DRUG:** Bi-Weekly Administration of ARQ 761
- **DRUG:** Two Consecutive Weeks Administration of ARQ 761 with one week of rest

## Key facts

- **NCT ID:** NCT01502800
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-29
- **Primary completion:** 2017-02
- **Final completion:** 2019-03
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502800, "Clinical Trial of ARQ 761 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01502800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*